Zubin Eapen

Chief Medical Officer, Element Science. Adjunct Associate Professor of Medicine, @DukeU

[Zubin Eapen @zeapen]

Big day for our patients. Element Science is thrilled to receive regulatory approval in Europe for the Jewel, a first of its kind Patch Wearable Cardioverter Defibrillator. Strong clinical trial results were key to achieving this milestone. https://t.co/GR8lKs28oG

[Zubin Eapen @zeapen]

@coconnormd Chris, we are thinking of you and your family. I know how much you loved her.

[Zubin Eapen @zeapen]

@ankeetbhatt and @JohnHummelEP discuss how the Jewel patch wearable cardioverter defibrillator can provide more security, more time to optimize heart failure meds before deciding on an ICD. #AHA23 #CardioTwitter

[Zubin Eapen @zeapen]

Congratulations to @JohnHummelEP @Drroxmehran @JavedButler1 and the Jewel IDE Study investigators and patients for demonstrating the safety and effectiveness of the Jewel, a novel patch wearable cardioverter defibrillator. #AHA23 #CardioTwitter

[Cardiology Today @CardiologyToday]

Jewel IDE:
Jewel adhesive-based wearable defibrillator:
➡️Inappropriate shocks low, met performance goal
➡️Cutaneous AEs low, met performance goal
➡️8 successful cardioversions, no deaths
#AHA23 @HeartNews @American_Heart #CardioTwitter

[Zubin Eapen @zeapen]

Enjoyed talking with HealthCare Business News about what Element Science, Inc. is doing to address the problem of sudden cardiac arrest.

In two days, the pivotal trial results of our novel wearable defibrillator will be shared at #aha23. https://t.co/IVZgqG5Uno

[Zubin Eapen @zeapen]

News: Element Science, Inc. will be part of the 2023 Scientific Sessions lineup for Late-Breaking & Featured Science. Join us on November 13 when we will share data on the safety and efficacy of the Jewel, a novel Patch Wearable Cardioverter Defibrillator. https://t.co/y7C6zCNDiz

[Zubin Eapen @zeapen]

Element Science is proud to work with committed cardiologists and patients who are helping determine the life-saving potential of an innovative technology like the Jewel. https://t.co/M4NvCVBIDS

[Zubin Eapen @zeapen]

Honored to join @DukeMedSchool Board of Visitors after having been a Duke med student, intern, resident, fellow, & faculty member. @MaryEKlotman and @TheDHVI highlighted today progress towards a pan-coronavirus vaccine. Proud to be part of this community
https://t.co/QRuRkPWNbL

[Zubin Eapen @zeapen]

4.8% increase in heart disease deaths is the largest increase since 2012. Remind me of early @nytimes piece by @hmkyale which highlighted that patients may have been delaying necessary care until their condition had worsened. https://t.co/DDGOvK0xUH https://t.co/KaCC3854u4

[Kevin Haynes @khaynes001]

Great publication working with great colleagues. @zeapen @ajnelson @emilycob We have room to go on improving utilization of guideline directed care. @HealthCoreRWE https://t.co/JzYHjzKtZs

[Zubin Eapen @zeapen]

Only 10 cases of anaphylaxis after administration of a reported 4,041,396 first doses of Moderna COVID-19 vaccine (2.5 cases per million doses administered)

[Jeffrey Flier @jflier]

Good news - pass it on! Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Moderna COVID-19 Vaccine — United States, December 21, 2020–January 10, 2021 | MMWR https://t.co/uJ5U3tzhPm

[Zubin Eapen @zeapen]

We owe a debt of gratitude to this group, all of the investigators, and all of the patients who are answering clinically meaningful questions in the appropriate way: with randomization. And magnitude of participation noted by @MartinLandray is impressive: https://t.co/tVVS7GcEDn

[Peter Horby @peterhorby.bsky.social @PeterHorby]

The RECOVERY Data Monitoring Committee reviewed data on patients randomised to convalescent plasma vs. usual care. The preliminary analysis based on 10,406 randomised patients with 1873 reported deaths shows no significant difference in the primary endpoint of 28-day mortality.

[Peter Horby @peterhorby.bsky.social @PeterHorby]

The RECOVERY Data Monitoring Committee reviewed data on patients randomised to convalescent plasma vs. usual care. The preliminary analysis based on 10,406 randomised patients with 1873 reported deaths shows no significant difference in the primary endpoint of 28-day mortality.

[Zubin Eapen @zeapen]

Element Science is hiring! We are seeking a Vice President of Clinical Affairs to lead clinical trials/research, clinical operations, and clinical engineering. Join us in 2021 and launch the pivotal trial for our flagship product. https://t.co/EiNCceF68i

[Zubin Eapen @zeapen]

A New Vaccine to Battle Covid-19 | NEJM. I will always feel fortunate to have worked in Dr. Barton Haynes's lab when I was a @DukeMedSchool student. https://t.co/uDrGZBQm1E

[Zubin Eapen @zeapen]

@denniskomd @hmkyale @YaleMed @CircOutcomes Congratulations @hmkyale ! Terrific news and well deserved

[Zubin Eapen @zeapen]

Element Science is hiring! We are seeking a Senior Clinical Project Manager to join our growing Clinical team. Come help us change the way care is delivered for high-risk cardiovascular patients.
https://t.co/FRolD7zBRk #job

[Zubin Eapen @zeapen]

@IHVInews @atwater_brett @coconnormd @_WayneBatchelor Congratulations @atwater_brett ! Excellent choice by @IHVInews @coconnormd

[Zubin Eapen @zeapen]

I'm honored to join the Element Science team to help high-risk cardiovascular patients transition from hospital to home. We are building a next-generation digital wearable platform to change the way care is delivered. https://t.co/sx8xqw7v4s

[Zubin Eapen @zeapen]

@HeartBobH Congratulations @HeartBobH to you and your family! Beautiful